GlassScriptPhysician profile
John A Kelly
NPI 1972952125
$10,163.45
in general payments reported to CMS, 2019-2025
47 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $1,106 · 2021: $1,894 · 2022: $1,560 · 2023: $1,874 · 2024: $1,836 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,354.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,250.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,023.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $874.91 | 2019-2025 | |
| Abbvie INC. | $724.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $717.93 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $602.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $565.43 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.70 | 2019-2025 | Jardiance |
| Amgen INC. | $494.40 | 2019-2025 | Otezla, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.01 | 2020-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $241.11 | 2019-2022 | |
| Esperion Therapeutics, INC. | $232.07 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $210.49 | 2020-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Astellas Pharma US INC | $210.26 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $188.29 | 2020-2024 | Freestyle Libre 3 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.